Financial Performance - The company's operating revenue for Q1 2022 was ¥38,090,182.58, representing a decrease of 57.09% compared to the same period last year[5]. - Total operating revenue for Q1 2022 was ¥38,090,182.58, a decrease of 57.0% compared to ¥88,763,204.08 in Q1 2021[21]. - Net profit for Q1 2022 was a loss of ¥7,232,998.53, compared to a profit of ¥22,426,173.56 in Q1 2021, representing a significant decline[22]. - The company reported a total comprehensive loss of ¥7,035,964.29 for Q1 2022, compared to a comprehensive income of ¥22,061,293.60 in Q1 2021[23]. - Basic and diluted earnings per share for Q1 2022 were both -¥0.08, compared to ¥0.28 in Q1 2021[23]. - Operating profit for Q1 2022 was ¥419,246.32, significantly down from ¥21,933,841.49 in Q1 2021[31]. - The net profit for Q1 2022 was a loss of ¥147,360.51, compared to a profit of ¥18,478,746.72 in Q1 2021[31]. Cash Flow and Investments - The net cash flow from operating activities was -¥18,775,283.32, primarily due to reduced revenue and increased R&D investments[10]. - The net cash flow from operating activities was -18,775,283.32 RMB, a significant decline compared to -4,232,062.58 RMB in the previous year, indicating a worsening operational cash flow situation[25]. - Cash received from sales of goods and services in Q1 2022 was ¥56,661,168.42, down 38.8% from ¥92,637,961.48 in Q1 2021[24]. - Total cash inflow from investment activities reached 786,814,946.45 RMB, a substantial increase from 256,050,152.64 RMB year-over-year, driven by other investment-related cash receipts of 783,396,660.00 RMB[25]. - The cash outflow for investment activities was 905,748,368.54 RMB, significantly higher than 307,815,110.11 RMB in the previous year, reflecting increased investment expenditures[25]. - The company reported a significant increase in investment activity cash inflow to ¥786,814,946.45 in Q1 2022, compared to ¥256,050,152.64 in Q1 2021[34]. - Total cash outflow from investment activities was ¥903,750,875.08 in Q1 2022, compared to ¥307,399,200.00 in Q1 2021[34]. Research and Development - Research and development expenses totaled ¥10,773,753.92, accounting for 28.28% of operating revenue, an increase of 21.22 percentage points year-on-year[6]. - Research and development expenses for Q1 2022 were ¥10,773,753.92, an increase of 72.5% from ¥6,262,597.54 in Q1 2021[21]. - Research and development expenses increased to ¥10,150,811.74 in Q1 2022, up 88.5% from ¥5,386,318.21 in Q1 2021[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥924,585,651.53, a decrease of 1.75% from the end of the previous year[6]. - The company's total assets amounted to RMB 924,585,651.53, a decrease from RMB 941,065,240.00 as of December 31, 2021, reflecting a decline of approximately 1.75%[16]. - The company's cash and cash equivalents were RMB 216,869,303.99, down from RMB 355,514,192.05, indicating a decrease of about 39.0%[16]. - Total liabilities as of Q1 2022 amounted to ¥59,176,234.81, a decrease from ¥70,164,253.35 in the previous year[19]. - The total liabilities decreased to 55,901,853.71 RMB from 65,182,854.84 RMB, showing a reduction in the company's debt levels[29]. - The company's total equity increased slightly to 851,473,124.06 RMB from 850,076,090.21 RMB, indicating stable shareholder value[29]. Shareholder Information - The company had a total of 6,252 common shareholders at the end of the reporting period[12]. - The top shareholder, LIU JIANQIANG, held 12,810,000 shares, representing 14.54% of the total shares[12]. Other Information - The company received government subsidies amounting to ¥229,511.33 during the reporting period[7]. - The company reported a non-recurring gain of ¥3,287,259.65 after tax, primarily from investment income[8]. - The company has not disclosed any new product or technology developments in this quarter[15]. - There are no significant mergers or acquisitions reported during this period[15].
康众医疗(688607) - 2022 Q1 - 季度财报